Consensus Vertex Pharmaceuticals Incorporated Sao Paulo

Stocks

VRTX34

BRVRTXBDR001

Pharmaceuticals

Delayed Sao Paulo 15:16:17 19/10/2026 BST			5-day change	1st Jan Change
79.36 ^BRL	-0.30%		+3.77%	+1.43%

10-20	Vertex Pharmaceuticals Incorporated Announces Appointment of Daniel Brennan as Member of the Board of Directors, Audit and Finance Committee	CI
10-15	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653	MT

d367e8f22a30a65ff5348ab.dhuXW246w89rwSwKohMBhiyaonvC23uS6QH7R83TF9A.J3jjKxtWqIkPlxlM0WdT9Wrz9T-tqyPWsF7WFqbgW5EOavwBD3SO_gW0FA~528c613e56dc88b8bf233fc3f3d5667b

Analysts' recommendations: Vertex Pharmaceuticals Incorporated

10-15	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653	MT
10-08	RBC Lifts Price Target on Vertex Pharmaceuticals to $576 From $570, Keeps Outperform Rating	MT
09-28	UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating	MT
09-23	TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
09-23	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $640 From $633, Maintains Buy Rating	MT
09-02	Evercore ISI Adjusts Vertex Pharmaceuticals Price Target to $600 From $535, Maintains Outperform Rating	MT
08-12	Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says	MT
08-11	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating	MT
08-11	Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals to $556 From $555, Maintains Buy Rating	MT
08-05	Rothschild & Co Redburn Adjusts Vertex Pharmaceuticals Price Target to $580 From $570	MT
08-04	Vertex Pharmaceuticals Seen Well Positioned Ahead of Pipeline Catalysts, UBS Says	MT
08-04	Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says	MT
08-04	RBC Capital Adjusts Price Target on Vertex Pharmaceuticals to $570 From $577, Maintains Outperform Rating	MT
08-04	Barclays Adjusts PT on Vertex Pharmaceuticals to $617 From $615, Maintains Overweight Rating	MT
08-04	Goldman Sachs Adjusts PT on Vertex Pharmaceuticals to $653 From $652, Maintains Buy Rating	MT
08-04	Stifel Adjusts Price Target on Vertex Pharmaceuticals to $500 From $466, Maintains Hold Rating	MT
08-04	Cantor Fitzgerald Adjusts PT on Vertex Pharmaceuticals to $595 From $590, Maintains Overweight Rating	MT
08-04	Canaccord Genuity Adjusts PT on Vertex Pharmaceuticals to $442 From $436, Maintains Hold Rating	MT
08-04	TD Cowen Adjusts Price Target on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
07-21	Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19	MT
07-20	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $652 From $641, Maintains Buy Rating	MT
07-13	UBS Adjusts Vertex Pharmaceuticals Price Target to $585 From $545, Maintains Buy Rating	MT
07-09	RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $577 From $570	MT
07-08	Jefferies Adjusts Vertex Pharmaceuticals Price Target to $610 From $580	MT
07-07	Vertex Pharmaceuticals' Acquisition of Crinetics Adds Rare-Disease Drugs, UBS Says	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+3.71%
	JOHNSON & JOHNSON					+7.73%
	ABBVIE INC.					-2.24%
	ROCHE HOLDING AG					-1.52%
	MERCK & CO., INC.					+6.92%
	NOVARTIS AG					-2.21%
	ASTRAZENECA PLC					+24.46%
	AMGEN INC.					-10.02%
	GILEAD SCIENCES, INC.					+2.33%
	Average					+3.24%
	Weighted average by Cap.					+3.43%